Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial.
This randomized, double-blinded, placebo-controlled trial demonstrated an improved time to ‘clinical stability’ in patients treated with prednisone for community acquired pneumonia. The study did not examine a clinically important primary outcome, and so the relevance of their findings is of questionable significance; prednisone is not yet ready to be considered the standard of care in community-acquired pneumonia.
By: Dr. Shahbaz Syed
(Presented March 2015)
By: Dr. Ian Stiell